Skip to main content
. 2019 Jun 28;5(2):57–61. doi: 10.1016/j.afos.2019.06.001

Fig. 2.

Fig. 2

Changes in urinary N-terminal telopeptide of type I collagen (NTX) before bisphosphonate (BP) treatment, before eldecalcitol (ELD) addition, and at 4 months after ELD addition. Before BP therapy, mean urinary NTX was 49.3 ± 25.9 nmol bone collagen equivalent (BCE)/mmol creatinine (Cr). This had decreased significantly to 25.0 ± 10.6 nmol BCE/mmol Cr prior to ELD commencement (P< 0.01) and was further significantly reduced after the addition of ELD to 17.0 ± 5.9 nmol BCE/mmol Cr (P= 0.01). *P < 0.05.